Prader Wili Syndrome

Shares of Zafgen Inc (NASDAQ: ZFGN) gained more than 14 percent early Monday morning after the company announced positive data from a Phase 3 trial evaluating the safety and efficacy of beloranib. The study evaluated the safety and efficacy of beloranib, a MetAP2 inhibitor, in patients with...